AdipoRaMab(Mitsubishi Tanabe Pharma)(AdipoRaMab(Mitsubishi Tanabe Pharma)) - 药物靶点：ADIPOR1 x ADIPOR2_在研适应症：2型糖尿病，代谢功能障碍相关的脂肪肝病_专利_临床

概要

基本信息

药物类型

单克隆抗体

别名

靶点

ADIPOR1 x ADIPOR2

作用机制

ADIPOR1激动剂(脂联素受体蛋白-1激动剂)、ADIPOR2激动剂(脂联素受体蛋白-2激动剂)

治疗领域

消化系统疾病内分泌与代谢疾病

在研适应症

2型糖尿病代谢功能障碍相关的脂肪肝病

非在研适应症-

原研机构

Mitsubishi Tanabe Pharma Corp.

在研机构

Mitsubishi Tanabe Pharma Corp.

非在研机构-

最高研发阶段临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 AdipoRaMab(Mitsubishi Tanabe Pharma) 相关的临床结果

登录后查看更多信息

100 项与 AdipoRaMab(Mitsubishi Tanabe Pharma) 相关的转化医学

登录后查看更多信息

100 项与 AdipoRaMab(Mitsubishi Tanabe Pharma) 相关的专利（医药）

登录后查看更多信息

1

项与 AdipoRaMab(Mitsubishi Tanabe Pharma) 相关的文献（医药）

2023-11-10·Science Advances

A monoclonal antibody activating AdipoR for type 2 diabetes and nonalcoholic steatohepatitis

Article

作者: Okada-Iwabu, Miki ; Wada, Kouichi ; Kadowaki, Takashi ; Oka, Kozo ; Asahara, Naomi ; Yamauchi, Toshimasa ; Iwabu, Masato

Adiponectin receptors, AdipoR1 and AdipoR2 are promising targets for the prevention and treatment of metabolic diseases. In this study, we aimed to establish agonistic antibodies against AdipoR1 and AdipoR2 with a long enough half-life to provide a means of improving poor medication adherence associated with preclinical small-molecule AdipoR agonists or existing antidiabetic drugs. Monoclonal antibodies were obtained by immunizing AdipoR knockout mice with human AdipoR-expressing cells. Of the antibodies shown to bind to both, an agonist antibody was obtained, which exhibited adenosine 5′-monophosphate–activated protein kinase–activating properties such as adiponectin and was named AdipoR-activating monoclonal antibody (AdipoRaMab). AdipoRaMab ameliorated glucose intolerance in high-fat diet–fed mice, which was not observed in AdipoR1·AdipoR2 double knockout mice. AdipoRaMab exhibited anti-inflammatory and antifibrotic effects in the nonalcoholic steatohepatitis (NASH) model, indicating its therapeutic potential in diabetes and in NASH. In addition, the results of this study indicated that AdipoRaMab may exert therapeutic effects even in a once-monthly dosing regimen through its humanization.

100 项与 AdipoRaMab(Mitsubishi Tanabe Pharma) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
2型糖尿病	临床前	日本	Mitsubishi Tanabe Pharma Corp.	2023-11-10
代谢功能障碍相关的脂肪肝病	临床前	日本	Mitsubishi Tanabe Pharma Corp.	2023-11-10